

# Miguel Hernn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7956509/publications.pdf>

Version: 2024-02-01

317  
papers

64,727  
citations

2962

96  
h-index

1096

239  
g-index

345  
all docs

345  
docs citations

345  
times ranked

73452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Separable Effects for Causal Inference in the Presence of Competing Events. <i>Journal of the American Statistical Association</i> , 2022, 117, 175-183.	1.8	45
2	Causal analyses of existing databases: no power calculations required. <i>Journal of Clinical Epidemiology</i> , 2022, 144, 203-205.	2.4	62
3	Revisiting the g-null Paradox. <i>Epidemiology</i> , 2022, 33, 114-120.	1.2	8
4	Multiply robust estimators of causal effects for survival outcomes. <i>Scandinavian Journal of Statistics</i> , 2022, 49, 1304-1328.	0.9	5
5	Mendelian Randomization With Repeated Measures of a Time-varying Exposure. <i>Epidemiology</i> , 2022, 33, 84-94.	1.2	9
6	SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment. <i>Aids</i> , 2022, 36, 161-168.	1.0	22
7	Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. <i>New England Journal of Medicine</i> , 2022, 386, 105-115.	13.9	182
8	Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. <i>Human Reproduction</i> , 2022, 37, 793-805.	0.4	8
9	Predicting counterfactual risks under hypothetical treatment strategies: an application to HIV. <i>European Journal of Epidemiology</i> , 2022, , 1.	2.5	7
10	Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data. <i>PLoS Computational Biology</i> , 2022, 18, e1009964.	1.5	8
11	Effectiveness and safety of intrauterine insemination vs. assisted reproductive technology: emulating a target trial using an observational database of administrative claims. <i>Fertility and Sterility</i> , 2022, 117, 981-991.	0.5	8
12	Comparison of Mortality Risk With Different Surgeon and Hospital Operative Volumes Among Individuals Undergoing Pancreatectomy by Emulating Target Trials in US Medicare Beneficiaries. <i>JAMA Network Open</i> , 2022, 5, e221766.	2.8	8
13	Causal analysis of existing databases: no power calculations required. Responses to Campbell, Morris and Mansournia, et al. <i>Journal of Clinical Epidemiology</i> , 2022, 144, 193.	2.4	1
14	Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. <i>New England Journal of Medicine</i> , 2022, 386, 1603-1614.	13.9	213
15	Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration. <i>American Journal of Epidemiology</i> , 2022, 191, 1652-1665.	1.6	10
16	Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. <i>JAMA Internal Medicine</i> , 2022, 182, 739.	2.6	17
17	BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 387, 227-236.	13.9	68
18	Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population. <i>American Journal of Epidemiology</i> , 2021, 190, 1632-1642.	1.6	35

#	ARTICLE	IF	CITATIONS
19	Parametric formula implementations for causal survival analyses. <i>Biometrics</i> , 2021, 77, 740-753.	0.8	14
20	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 41.	2.6	385
21	A population-based controlled experiment assessing the epidemiological impact of digital contact tracing. <i>Nature Communications</i> , 2021, 12, 587.	5.8	98
22	Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. <i>Intensive Care Medicine</i> , 2021, 47, 208-221.	3.9	143
23	Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure*. <i>Critical Care Medicine</i> , 2021, 49, 1026-1037.	0.4	64
24	Two Pandemics, Two Surveys in the United States and in Spain. <i>American Journal of Public Health</i> , 2021, 111, 414-415.	1.5	4
25	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 581-582.	2.0	16
26	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. <i>New England Journal of Medicine</i> , 2021, 384, 1412-1423.	13.9	2,179
27	Estimating the effect of nutritional interventions using observational data: the American Heart Association's 2020 Dietary Goals and mortality. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 690-703.	2.2	28
28	Critical Care Requirements Under Uncontrolled Transmission of SARS-CoV-2. <i>American Journal of Public Health</i> , 2021, 111, 923-926.	1.5	9
29	Head-to-head comparison of first-line FOLFIRINOX versus gemcitabine plus nabpaclitaxel (GN) in advanced pancreatic cancer (APC): A target trial emulation using Canadian real-world data.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18713-e18713.	0.8	0
30	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 622-632.	2.0	89
31	Strengthening Health Services Research Using Target Trial Emulation: An Application to Volume-Outcomes Studies. <i>American Journal of Epidemiology</i> , 2021, 190, 2453-2460.	1.6	11
32	Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 967-975.	1.9	14
33	ENE-COVID nationwide serosurvey served to characterize asymptomatic infections and to develop a symptom-based risk score to predict COVID-19. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 240-254.	2.4	12
34	Estimating optimal dynamic treatment strategies under resource constraints using dynamic marginal structural models. <i>Statistics in Medicine</i> , 2021, 40, 4996-5005.	0.8	3
35	Comparing Effect Estimates in Randomized Trials and Observational Studies From the Same Population: An Application to Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e020357.	1.6	14
36	Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States. <i>Cell Reports Medicine</i> , 2021, 2, 100376.	3.3	8

#	ARTICLE	IF	CITATIONS
37	Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. <i>New England Journal of Medicine</i> , 2021, 385, 1078-1090.	13.9	735
38	A generalized theory of separable effects in competing event settings. <i>Lifetime Data Analysis</i> , 2021, 27, 588-631.	0.4	19
39	Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. <i>Nature Medicine</i> , 2021, 27, 1693-1695.	15.2	222
40	Effects of COVID-19 pandemic on mental health outcomes in a cohort of early psychosis patients. <i>Microbial Biotechnology</i> , 2021, 15, 1799-1802.	0.9	17
41	Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 2101-2103.	13.9	82
42	Methods of Public Health Research – Strengthening Causal Inference from Observational Data. <i>New England Journal of Medicine</i> , 2021, 385, 1345-1348.	13.9	111
43	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. <i>Lancet, The</i> , 2021, 398, 2093-2100.	6.3	748
44	Instrumental variable estimation for a time-varying treatment and a time-to-event outcome via structural nested cumulative failure time models. <i>BMC Medical Research Methodology</i> , 2021, 21, 258.	1.4	11
45	Win-Win: Reconciling Social Epidemiology and Causal Inference. <i>American Journal of Epidemiology</i> , 2020, 189, 167-170.	1.6	28
46	Galea and Hernández Respond to “Brings to the Table,” “Differential Measurement Error,” and “Causal Inference in Social Epidemiology.” <i>American Journal of Epidemiology</i> , 2020, 189, 183-184.	1.6	5
47	Weight Gain After Smoking Cessation and Lifestyle Strategies to Reduce it. <i>Epidemiology</i> , 2020, 31, 7-14.	1.2	16
48	Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons. <i>Epidemiology</i> , 2020, 31, e49-e51.	1.2	24
49	Emulating a target trial in case-control designs: an application to statins and colorectal cancer. <i>International Journal of Epidemiology</i> , 2020, 49, 1637-1646.	0.9	29
50	Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. <i>JAMA Internal Medicine</i> , 2020, 180, 1436.	2.6	711
51	Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. <i>BMJ, The</i> , 2020, 371, m4509.	3.0	150
52	Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years. <i>Annals of Internal Medicine</i> , 2020, 172, 381.	2.0	34
53	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2020, 173, 536-541.	2.0	280
54	Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations. <i>Epidemiology</i> , 2020, 31, 614-619.	1.2	30

#	ARTICLE	IF	CITATIONS
55	Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 3061-3071.	2.6	89
56	The Effect of Prenatal Treatments on Offspring Events in the Presence of Competing Events. <i>Epidemiology</i> , 2020, 31, 636-643.	1.2	20
57	A Graphical Description of Partial Exchangeability. <i>Epidemiology</i> , 2020, 31, 365-368.	1.2	13
58	Why Test for Proportional Hazards?. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1401.	3.8	221
59	Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens. <i>JAMA Network Open</i> , 2020, 3, e200452.	2.8	49
60	gfoRmula: An R Package for Estimating the Effects of Sustained Treatment Strategies via the Parametric g-formula. <i>Patterns</i> , 2020, 1, 100008.	3.1	29
61	Counterfactual prediction is not only for causal inference. <i>European Journal of Epidemiology</i> , 2020, 35, 615-617.	2.5	25
62	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. <i>Lancet</i> , 2020, 396, 535-544.	6.3	1,465
63	The Challenges of Parameterizing Direct Effects in Individual-Level Simulation Models. <i>Medical Decision Making</i> , 2020, 40, 106-111.	1.2	7
64	A causal framework for classical statistical estimands in failure-time settings with competing events. <i>Statistics in Medicine</i> , 2020, 39, 1199-1236.	0.8	138
65	Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. <i>Contemporary Clinical Trials</i> , 2020, 90, 105937.	0.8	9
66	Extending inferences from a randomized trial to a new target population. <i>Statistics in Medicine</i> , 2020, 39, 1999-2014.	0.8	94
67	Toward Causally Interpretable Meta-analysis. <i>Epidemiology</i> , 2020, 31, 334-344.	1.2	41
68	Hypothetical Lifestyle Strategies in Middle-Aged Women and the Long-Term Risk of Stroke. <i>Stroke</i> , 2020, 51, 1381-1387.	1.0	15
69	Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial. <i>Clinical Trials</i> , 2020, 17, 570-575.	0.7	6
70	Inverse Probability Weighted Estimation of Risk Under Representative Interventions in Observational Studies. <i>Journal of the American Statistical Association</i> , 2019, 114, 938-947.	1.8	21
71	Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study. <i>Trials</i> , 2019, 20, 552.	0.7	14
72	Avoidable flaws in observational analyses: an application to statins and cancer. <i>Nature Medicine</i> , 2019, 25, 1601-1606.	15.2	185

#	ARTICLE	IF	CITATIONS
73	The Effect of the Opioid Epidemic on Donation After Circulatory Death Transplantation Outcomes. <i>Transplantation</i> , 2019, 103, 973-979.	0.5	12
74	The meaning of confounding adjustment in the presence of multiple versions of treatment: an application to organ transplantation. <i>European Journal of Epidemiology</i> , 2019, 34, 225-233.	2.5	7
75	Extending inferences from a randomized trial to a target population. <i>European Journal of Epidemiology</i> , 2019, 34, 719-722.	2.5	71
76	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	1.6	75
77	A Second Chance to Get Causal Inference Right: A Classification of Data Science Tasks. <i>Chance</i> , 2019, 32, 42-49.	0.1	247
78	Comment: Spherical Cows in a Vacuum: Data Analysis Competitions for Causal Inference. <i>Statistical Science</i> , 2019, 34, .	1.6	6
79	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
80	Estimating the Effect of Preventive Services With Databases of Administrative Claims: Reasons to Be Concerned. <i>American Journal of Epidemiology</i> , 2019, 188, 1764-1767.	1.6	3
81	RoB 2: a revised tool for assessing risk of bias in randomised trials. <i>BMJ: British Medical Journal</i> , 2019, 366, 14898.	2.4	10,984
82	On the Relation Between G-formula and Inverse Probability Weighting Estimators for Generalizing Trial Results. <i>Epidemiology</i> , 2019, 30, 807-812.	1.2	18
83	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 314-320.	0.9	6
84	Guideline-Based Physical Activity and Survival Among US Men With Nonmetastatic Prostate Cancer. <i>American Journal of Epidemiology</i> , 2019, 188, 579-586.	1.6	16
85	Generalizing Causal Inferences from Individuals in Randomized Trials to All Trial-Eligible Individuals. <i>Biometrics</i> , 2019, 75, 685-694.	0.8	86
86	The C-Word: The More We Discuss It, the Less Dirty It Sounds. <i>American Journal of Public Health</i> , 2018, 108, 625-626.	1.5	19
87	Assessment of recording bias in pregnancy studies using health care databases: An application to neurologic conditions. <i>Paediatric and Perinatal Epidemiology</i> , 2018, 32, 281-286.	0.8	13
88	Electronic medical records can be used to emulate target trials of sustained treatment strategies. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 12-22.	2.4	72
89	Correspondence Between Results and Aims of Funding Support in EPIDEMIOLOGY Articles. <i>Epidemiology</i> , 2018, 29, 1-4.	1.2	3
90	How to estimate the effect of treatment duration on survival outcomes using observational data. <i>BMJ: British Medical Journal</i> , 2018, 360, k182.	2.4	86

#	ARTICLE	IF	CITATIONS
91	Causal null hypotheses of sustained treatment strategies: What can be tested with an instrumental variable?. <i>European Journal of Epidemiology</i> , 2018, 33, 723-728.	2.5	33
92	The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data. <i>American Journal of Public Health</i> , 2018, 108, 616-619.	1.5	323
93	Cautions as Regulators Move to End Exclusive Reliance on Intention to Treat. <i>Annals of Internal Medicine</i> , 2018, 168, 515.	2.0	25
94	The challenging interpretation of instrumental variable estimates under monotonicity. <i>International Journal of Epidemiology</i> , 2018, 47, 1289-1297.	0.9	45
95	Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. <i>Health Services Research</i> , 2018, 53, 1900-1918.	1.0	26
96	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 102-109.	0.9	2
97	Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. <i>JAMA Oncology</i> , 2018, 4, 63.	3.4	134
98	Using Observational Data to Calibrate Simulation Models. <i>Medical Decision Making</i> , 2018, 38, 212-224.	1.2	10
99	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018, 32, 327-335.	1.0	13
100	Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes. <i>Aids</i> , 2018, 32, 113-120.	1.0	35
101	Association of Statin Use With Overall and Cancer Survival—Reply. <i>JAMA Oncology</i> , 2018, 4, 1016.	3.4	2
102	Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men. <i>Annals of Internal Medicine</i> , 2018, 168, 775-782.	2.0	117
103	Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials. <i>Journal of Clinical Epidemiology</i> , 2018, 103, 10-21.	2.4	30
104	Improved adherence adjustment in the Coronary Drug Project. <i>Trials</i> , 2018, 19, 158.	0.7	20
105	Partial Identification of the Average Treatment Effect Using Instrumental Variables: Review of Methods for Binary Instruments, Treatments, and Outcomes. <i>Journal of the American Statistical Association</i> , 2018, 113, 933-947.	1.8	59
106	Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. <i>New England Journal of Medicine</i> , 2018, 378, e34.	13.9	2,065
107	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	2.1	10
108	Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years. <i>Annals of Internal Medicine</i> , 2017, 166, 758.	2.0	3

#	ARTICLE	IF	CITATIONS
109	Nature as a Trialist?. <i>Epidemiology</i> , 2017, 28, 653-659.	1.2	115
110	Invited Commentary: Selection Bias Without Colliders. <i>American Journal of Epidemiology</i> , 2017, 185, 1048-1050.	1.6	73
111	Biases in Randomized Trials. <i>Epidemiology</i> , 2017, 28, 54-59.	1.2	198
112	Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years. <i>Annals of Internal Medicine</i> , 2017, 166, 18.	2.0	99
113	Per-Protocol Analyses of Pragmatic Trials. <i>New England Journal of Medicine</i> , 2017, 377, 1391-1398.	13.9	358
114	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	0.9	12
115	The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. <i>European Journal of Epidemiology</i> , 2017, 32, 495-500.	2.5	96
116	The Authors Respond. <i>Epidemiology</i> , 2017, 28, e41.	1.2	0
117	A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. <i>American Journal of Epidemiology</i> , 2017, 186, 131-142.	1.6	57
118	3. Observational Studies Analyzed Like Randomized Trials and Vice Versa. , 2017, , 107-128.		2
119	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. <i>Aids</i> , 2016, 30, 2659-2663.	1.0	21
120	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 214-221.	0.9	22
121	Population-Based Colonoscopy Screening for Colorectal Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 894.	2.6	258
122	Rationale and design of the European Polyp Surveillance (EPoS) trials. <i>Endoscopy</i> , 2016, 48, 571-578.	1.0	90
123	Does water kill? A call for less casual causal inferences. <i>Annals of Epidemiology</i> , 2016, 26, 674-680.	0.9	123
124	The continuing uncertainty about cancer risk in inflammatory bowel disease. <i>Gut</i> , 2016, 65, 889-893.	6.1	52
125	Colonoscopy and Risk of Infective Endocarditis in the Elderly. <i>Journal of the American College of Cardiology</i> , 2016, 68, 570-571.	1.2	2
126	Re: Causality and causal inference in epidemiology: the need for a pluralistic approach. <i>International Journal of Epidemiology</i> , 2016, 45, dyw162.	0.9	14



#	ARTICLE	IF	CITATIONS
127	Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 70-75.	2.4	449
128	Smoking cessation and long-term weight gain in the Framingham Heart Study: an application of the parametric g-formula for a continuous outcome. <i>European Journal of Epidemiology</i> , 2016, 31, 1223-1229.	2.5	31
129	ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. <i>BMJ</i> , The, 2016, 355, i4919.	3.0	8,654
130	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. <i>Medicine (United States)</i> , 2016, 95, e5133.	0.4	3
131	Atazanavir exposure in utero and neurodevelopment in infants. <i>Aids</i> , 2016, 30, 1267-1277.	1.0	28
132	Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials. <i>Clinical Trials</i> , 2016, 13, 372-378.	0.7	40
133	Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. <i>American Journal of Epidemiology</i> , 2016, 183, 758-764.	1.6	1,291
134	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43
135	Infective endocarditis and cancer in the elderly. <i>European Journal of Epidemiology</i> , 2016, 31, 41-49.	2.5	22
136	Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 547-551.	0.5	119
137	Can big data tell us what clinical trials don't? Screening colonoscopy to prevent colorectal cancer in individuals aged 70-79 years. <i>Journal of Clinical Oncology</i> , 2016, 34, 1563-1563.	0.8	0
138	CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. <i>Aids</i> , 2015, 29, 2109-2119.	1.0	13
139	Bounding the per-protocol effect in randomized trials: an application to colorectal cancer screening. <i>Trials</i> , 2015, 16, 541.	0.7	22
140	Definition and Evaluation of the Monotonicity Condition for Preference-based Instruments. <i>Epidemiology</i> , 2015, 26, 414-420.	1.2	32
141	Discussion of "On Bayesian Estimation of Marginal Structural Models". <i>Biometrics</i> , 2015, 71, 296-299.	0.8	19
142	Ensemble learning of inverse probability weights for marginal structural modeling in large observational datasets. <i>Statistics in Medicine</i> , 2015, 34, 106-117.	0.8	43
143	Learning how to improve healthcare delivery: the Swedish Quality Registers. <i>Journal of Internal Medicine</i> , 2015, 277, 87-89.	2.7	15
144	Selecting on Treatment: A Pervasive Form of Bias in Instrumental Variable Analyses. <i>American Journal of Epidemiology</i> , 2015, 181, 191-197.	1.6	52

#	ARTICLE	IF	CITATIONS
145	Boosted Lopinavir <sup>®</sup> Versus Boosted Atazanavir <sup>®</sup> Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	2.9	6
146	Longitudinal Causal Inference. , 2015, , 340-344.		3
147	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , the, 2015, 2, e335-e343.	2.1	52
148	Ebola and beyond. <i>Science</i> , 2015, 348, 46-48.	6.0	18
149	Counterpoint: Epidemiology to Guide Decision-Making: Moving Away From Practice-Free Research. <i>American Journal of Epidemiology</i> , 2015, 182, 834-839.	1.6	42
150	Methods to Estimate the Comparative Effectiveness of Clinical Strategies that Administer the Same Intervention at Different Times. <i>Current Epidemiology Reports</i> , 2015, 2, 149-161.	1.1	15
151	Why post <sup>®</sup> progression survival and post <sup>®</sup> relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 2444-2447.	2.3	11
152	Should Patients with Chronic Disease Be Told to Gain Weight? The Obesity Paradox and Selection Bias. <i>American Journal of Medicine</i> , 2015, 128, 334-336.	0.6	84
153	Invited Commentary: Agent-Based Models for Causal Inference—Reweighting Data and Theory in Epidemiology. <i>American Journal of Epidemiology</i> , 2015, 181, 103-105.	1.6	48
154	Weight loss and coronary heart disease. <i>Epidemiology</i> , 2015, 27, 1.	1.2	24
155	Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003846.	1.3	170
156	Major Declines in Epoetin Dosing after Prospective Payment System Based on Dialysis Facility Organizational Status. <i>American Journal of Nephrology</i> , 2014, 40, 554-560.	1.4	13
157	Evaluation of the Duplication of Staging CT Scans for Localized Colon Cancer in a Medicare Population. <i>Medical Care</i> , 2014, 52, 963-968.	1.1	1
158	Body Mass Index, Diabetes, and Mortality in French Women. <i>Epidemiology</i> , 2014, 25, 10-14.	1.2	76
159	Effect of Flexible Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 606.	3.8	349
160	Invited Commentary: Composite Outcomes as an Attempt to Escape From Selection Bias and Related Paradoxes. <i>American Journal of Epidemiology</i> , 2014, 179, 368-370.	1.6	34
161	Commentary: A structural approach to Berkson <sup>™</sup> 's fallacy and a guide to a history of opinions about it. <i>International Journal of Epidemiology</i> , 2014, 43, 515-521.	0.9	41
162	Incidence of Adult-onset Asthma After Hypothetical Interventions on Body Mass Index and Physical Activity: An Application of the Parametric G-Formula. <i>American Journal of Epidemiology</i> , 2014, 179, 20-26.	1.6	40

#	ARTICLE	IF	CITATIONS
163	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014, 83, 134-141.	1.5	112
164	Think Globally, Act Globally: An Epidemiologist's Perspective on Instrumental Variable Estimation. <i>Statistical Science</i> , 2014, 29, 371-374.	1.6	38
165	Identification, Estimation and Approximation of Risk under Interventions that Depend on the Natural Value of Treatment Using Observational Data. <i>Epidemiologic Methods</i> , 2014, 3, 1-19.	0.8	84
166	Estimating the Per-Exposure Effect of Infectious Disease Interventions. <i>Epidemiology</i> , 2014, 25, 134-138.	1.2	22
167	Comparative Effectiveness of Two Anemia Management Strategies for Complex Elderly Dialysis Patients. <i>Medical Care</i> , 2014, 52, S132-S139.	1.1	20
168	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5003-5003.	0.8	12
169	Oseltamivir Effect on Antibiotic-Treated Lower Respiratory Tract Complications in Virologically Positive Randomized Trial Participants. <i>Clinical Infectious Diseases</i> , 2013, 57, 1368-1369.	2.9	10
170	Matched designs and causal diagrams. <i>International Journal of Epidemiology</i> , 2013, 42, 860-869.	0.9	114
171	Causal Inference in Public Health. <i>Annual Review of Public Health</i> , 2013, 34, 61-75.	7.6	251
172	Statins and Risk of Diabetes. <i>Diabetes Care</i> , 2013, 36, 1236-1240.	4.3	64
173	Changes in Fish Consumption in Midlife and the Risk of Coronary Heart Disease in Men and Women. <i>American Journal of Epidemiology</i> , 2013, 178, 382-391.	1.6	52
174	From "Big Epidemiology" to "Colossal Epidemiology". <i>Epidemiology</i> , 2013, 24, 344-345.	1.2	10
175	Commentary. <i>Epidemiology</i> , 2013, 24, 370-374.	1.2	154
176	Hypothetical Midlife Interventions in Women and Risk of Type 2 Diabetes. <i>Epidemiology</i> , 2013, 24, 122-128.	1.2	55
177	Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease. <i>Statistical Methods in Medical Research</i> , 2013, 22, 70-96.	0.7	192
178	β-Blocker Use for Patients With or at Risk for Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 438.	3.8	0
179	Causal inference under multiple versions of treatment. <i>Journal of Causal Inference</i> , 2013, 1, 1-20.	0.5	148
180	The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration. <i>Aids</i> , 2013, 27, 2169-2170.	1.0	4

#	ARTICLE	IF	CITATIONS
181	Randomized Trials Analyzed as Observational Studies. <i>Annals of Internal Medicine</i> , 2013, 159, 560-2.	2.0	125
182	Effectiveness of Patient Adherence Groups as a Model of Care for Stable Patients on Antiretroviral Therapy in Khayelitsha, Cape Town, South Africa. <i>PLoS ONE</i> , 2013, 8, e56088.	1.1	172
183	The NordICC Study: Rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. <i>Endoscopy</i> , 2012, 44, 695-702.	1.0	149
184	Commentary. <i>Epidemiology</i> , 2012, 23, 785-786.	1.2	8
185	Panel discussion 2. <i>Clinical Trials</i> , 2012, 9, 66-79.	0.7	0
186	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, 1364-1372.	2.9	58
187	Results on Differential and Dependent Measurement Error of the Exposure and the Outcome Using Signed Directed Acyclic Graphs. <i>American Journal of Epidemiology</i> , 2012, 175, 1303-1310.	1.6	63
188	Beyond exchangeability: The other conditions for causal inference in medical research. <i>Statistical Methods in Medical Research</i> , 2012, 21, 3-5.	0.7	48
189	Beyond the intention-to-treat in comparative effectiveness research. <i>Clinical Trials</i> , 2012, 9, 48-55.	0.7	348
190	We Are Number One But Nobody Cares—That's Good. <i>Epidemiology</i> , 2012, 23, 509.	1.2	4
191	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 428-437.	0.9	119
192	Reply to “Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial”™. <i>Aids</i> , 2012, 26, 2262-2263.	1.0	0
193	Apparent declining efficacy in randomized trials. <i>Aids</i> , 2012, 26, 123-126.	1.0	35
194	Comments on Lauer's “How the debate about comparative effectiveness research should impact the future of clinical trials”™. <i>Statistics in Medicine</i> , 2012, 31, 3060-3061.	0.8	0
195	Structural Nested Cumulative Failure Time Models to Estimate the Effects of Interventions. <i>Journal of the American Statistical Association</i> , 2012, 107, 886-900.	1.8	34
196	Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. <i>American Journal of Epidemiology</i> , 2012, 175, 250-262.	1.6	205
197	The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. <i>Statistics in Medicine</i> , 2012, 31, 2000-2009.	0.8	89
198	Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 13-20.	0.9	28

#	ARTICLE	IF	CITATIONS
199	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
200	Compound Treatments and Transportability of Causal Inference. <i>Epidemiology</i> , 2011, 22, 368-377.	1.2	206
201	With Great Data Comes Great Responsibility. <i>Epidemiology</i> , 2011, 22, 290-291.	1.2	55
202	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. <i>Annals of Internal Medicine</i> , 2011, 154, 509.	2.0	205
203	Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2011, 108, 1362-1370.	0.7	448
204	Comparative Effectiveness of Dynamic Treatment Regimes: An Application of the Parametric G-Formula. <i>Statistics in Biosciences</i> , 2011, 3, 119-143.	0.6	112
205	Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 849-857.	0.9	75
206	Letter in response to Schneeweiss and Rassen on the high-dimensional propensity score approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1112-1112.	0.9	0
207	Oseltamivir and Risk of Lower Respiratory Tract Complications in Patients With Flu Symptoms: A Meta-analysis of Eleven Randomized Clinical Trials. <i>Clinical Infectious Diseases</i> , 2011, 53, 277-279.	2.9	110
208	Reply to Cochrane Neuraminidase Inhibitors Review Team. <i>Clinical Infectious Diseases</i> , 2011, 53, 1303-1304.	2.9	4
209	Editorial: Epidemiologic Studies, Warts and All, Are Our Best Chance. <i>Epidemiology</i> , 2011, 22, 636-637.	1.2	5
210	The Simpson's paradox unraveled. <i>International Journal of Epidemiology</i> , 2011, 40, 780-785.	0.9	149
211	High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. <i>Kidney International</i> , 2011, 80, 663-669.	2.6	41
212	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010, 24, 123-137.	1.0	360
213	The Hazards of Hazard Ratios. <i>Epidemiology</i> , 2010, 21, 13-15.	1.2	884
214	Estimating Absolute Risks in the Presence of Nonadherence. <i>Epidemiology</i> , 2010, 21, 528-539.	1.2	57
215	When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data. <i>International Journal of Biostatistics</i> , 2010, 6, Article 18.	0.4	160
216	Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. <i>Annals of Internal Medicine</i> , 2010, 152, 211.	2.0	97

#	ARTICLE	IF	CITATIONS
217	Relation between three classes of structural models for the effect of a time-varying exposure on survival. <i>Lifetime Data Analysis</i> , 2010, 16, 71-84.	0.4	47
218	Caseâ€œonly geneâ€œenvironment interaction studies: when does association imply mechanistic interaction?. <i>Genetic Epidemiology</i> , 2010, 34, 327-334.	0.6	31
219	Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1249-1252.	0.9	92
220	Early Life Factors and Adult-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 32-37.	1.0	18
221	More on Selection Bias. <i>Epidemiology</i> , 2010, 21, 430-431.	1.2	0
222	Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study. <i>BMC Neurology</i> , 2010, 10, 6.	0.8	47
223	Invited Commentary: Causal Diagrams and Measurement Bias. <i>American Journal of Epidemiology</i> , 2009, 170, 959-962.	1.6	139
224	Prednisone, Lupus Activity, and Permanent Organ Damage. <i>Journal of Rheumatology</i> , 2009, 36, 560-564.	1.0	191
225	Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. <i>International Journal of Epidemiology</i> , 2009, 38, 1599-1611.	0.9	235
226	A Correction Regarding Bibliographic Impact Factors. <i>Epidemiology</i> , 2009, 20, 785.	1.2	1
227	Epidemiology, Data Sharing, and the Challenge of Scientific Replication. <i>Epidemiology</i> , 2009, 20, 167-168.	1.2	34
228	Observation plans in longitudinal studies with time-varying treatments. <i>Statistical Methods in Medical Research</i> , 2009, 18, 27-52.	0.7	73
229	Estimated Effect of Epoetin Dosage on Survival among Elderly Hemodialysis Patients in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 638-644.	2.2	46
230	Incidence and lifetime risk of motor neuron disease in the United Kingdom: a populationâ€œbased study. <i>European Journal of Neurology</i> , 2009, 16, 745-751.	1.7	168
231	Impact Factor. <i>Epidemiology</i> , 2009, 20, 317-318.	1.2	21
232	Early versus deferred antiretroviral therapy for HIV. <i>New England Journal of Medicine</i> , 2009, 361, 822-3; author reply 823-4.	13.9	9
233	From causal diagrams to birth weight-specific curves of infant mortality. <i>European Journal of Epidemiology</i> , 2008, 23, 163-166.	2.5	38
234	Perinatal factors and adultâ€œonset lupus. <i>Arthritis and Rheumatism</i> , 2008, 59, 1155-1161.	6.7	25

#	ARTICLE	IF	CITATIONS
235	Constructing Inverse Probability Weights for Marginal Structural Models. American Journal of Epidemiology, 2008, 168, 656-664.	1.6	1,880
236	Temporal trends in the incidence of multiple sclerosis. Neurology, 2008, 71, 129-135.	1.5	587
237	Long-Term Effectiveness of Highly Active Antiretroviral Therapy on the Survival of Children and Adolescents with HIV Infection: A 10-Year Follow-Up Study. Clinical Infectious Diseases, 2008, 46, 507-515.	2.9	186
238	Cigarette Smoking and Dementia. Epidemiology, 2008, 19, 448-450.	1.2	140
239	Authors' Response, Part I: Observational Studies Analyzed Like Randomized Experiments. Epidemiology, 2008, 19, 789-792.	1.2	26
240	Long-Term Effects of Highly Active Antiretroviral Therapy on CD4+Cell Evolution among Children and Adolescents Infected with HIV: 5 Years and Counting. Clinical Infectious Diseases, 2008, 46, 1751-1760.	2.9	82
241	The effect of epoetin dose on hematocrit. Kidney International, 2008, 73, 347-353.	2.6	26
242	A Structural Approach to the Familial Coaggregation of Disorders. Epidemiology, 2008, 19, 431-439.	1.2	32
243	Causal Inference from Longitudinal Studies with Baseline Randomization. International Journal of Biostatistics, 2008, 4, Article 22.	0.4	88
244	Response to "Regarding the effect of epoetin dose on hematocrit". Kidney International, 2008, 74, 827-828.	2.6	0
245	Observational Studies Analyzed Like Randomized Experiments. Epidemiology, 2008, 19, 766-779.	1.2	668
246	Epidemiologists (of All People) Should Question Journal Impact Factors. Epidemiology, 2008, 19, 366-368.	1.2	51
247	Causal Directed Acyclic Graphs and the Direction of Unmeasured Confounding Bias. Epidemiology, 2008, 19, 720-728.	1.2	179
248	Estimation of the causal effects of time-varying exposures. Chapman & Hall/CRC Interdisciplinary Statistics Series, 2008, , 553-599.	0.4	95
249	Gout and risk of Parkinson disease. Neurology, 2007, 69, 1696-1700.	1.5	158
250	Determining the Effect of Highly Active Antiretroviral Therapy on Changes in Human Immunodeficiency Virus Type 1 RNA Viral Load using a Marginal Structural Left-censored Mean Model. American Journal of Epidemiology, 2007, 166, 219-227.	1.6	48
251	Epoetin Dosing and Dialysis Facility Ownership"Reply. JAMA - Journal of the American Medical Association, 2007, 298, 861.	3.8	0
252	Invited Commentary: Effect Modification by Time-varying Covariates. American Journal of Epidemiology, 2007, 166, 994-1002.	1.6	40



#	ARTICLE	IF	CITATIONS
253	Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1667.	3.8	104
254	Malnutrition Among Children Younger Than 5 Years-Old in Conflict Zones of Chiapas, Mexico. <i>American Journal of Public Health</i> , 2007, 97, 229-232.	1.5	22
255	Armed Conflict and Poverty in Central America. <i>Epidemiology</i> , 2007, 18, 673-677.	1.2	9
256	Rejoinder on "hepatitis B vaccination and multiple sclerosis the jury is still out". <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 707-708.	0.9	3
257	Allergy, family history of autoimmune diseases, and the risk of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2007, 117, 070901051948003-???	1.0	34
258	Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis: The Authors Respond. <i>American Journal of Kidney Diseases</i> , 2007, 50, 538-541.	2.1	1
259	From counterfactuals to sufficient component causes and vice versa. <i>European Journal of Epidemiology</i> , 2007, 21, 855-858.	2.5	40
260	Incidence of multiple sclerosis in the United Kingdom. <i>Journal of Neurology</i> , 2007, 254, 1736-1741.	1.8	77
261	Estimating causal effects from epidemiological data. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 578-586.	2.0	731
262	Hepatitis B vaccination and multiple sclerosis: the jury is still out. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 653-655.	0.9	22
263	Comparison of Dynamic Treatment Regimes via Inverse Probability Weighting. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 237-242.	1.2	210
264	Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. <i>Movement Disorders</i> , 2006, 21, 1002-1007.	2.2	77
265	Instruments for Causal Inference. <i>Epidemiology</i> , 2006, 17, 360-372.	1.2	753
266	Smoking, Snuff Dipping and the Risk of Amyotrophic Lateral Sclerosis " A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2006, 27, 217-221.	1.1	48
267	Tetanus vaccination and risk of multiple sclerosis: A systematic review. <i>Neurology</i> , 2006, 67, 212-215.	1.5	45
268	THREE AUTHORS REPLY. <i>American Journal of Epidemiology</i> , 2006, 164, 1253-1254.	1.6	0
269	Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. <i>Neurology</i> , 2006, 66, 572-575.	1.5	49
270	Antibiotic Use and Risk of Multiple Sclerosis. <i>American Journal of Epidemiology</i> , 2006, 163, 997-1002.	1.6	46



#	ARTICLE	IF	CITATIONS
271	The Birth Weight "Paradox" Uncovered?. American Journal of Epidemiology, 2006, 164, 1115-1120.	1.6	303
272	Hernandez-Diaz et al. Respond to "The Perils of Birth Weight". American Journal of Epidemiology, 2006, 164, 1124-1125.	1.6	5
273	Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology, 2006, 66, 1097-1099.	1.5	133
274	Discussion on "Statistical Issues Arising in the Women's Health Initiative". Biometrics, 2005, 61, 922-930.	0.8	28
275	Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiology and Drug Safety, 2005, 14, 477-491.	0.9	147
276	Recent Use of Oral Contraceptives and the Risk of Multiple Sclerosis. Archives of Neurology, 2005, 62, 1362.	4.9	128
277	Invited Commentary: Hypothetical Interventions to Define Causal Effects—Afterthought or Prerequisite?. American Journal of Epidemiology, 2005, 162, 618-620.	1.6	110
278	Cigarette smoking and the progression of multiple sclerosis. Brain, 2005, 128, 1461-1465.	3.7	242
279	Marginal Structural Models for Estimating the Effect of Highly Active Antiretroviral Therapy Initiation on CD4 Cell Count. American Journal of Epidemiology, 2005, 162, 471-478.	1.6	106
280	Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet, The, 2005, 366, 378-384.	6.3	526
281	Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study. Journal of the American Society of Nephrology: JASN, 2005, 16, 1115-1125.	3.0	756
282	Controlling for Time-dependent Confounding using Marginal Structural Models. The Stata Journal, 2004, 4, 402-420.	0.9	178
283	Obesity and the Risk of Parkinson's Disease. American Journal of Epidemiology, 2004, 159, 547-555.	1.6	91
284	Folate Intake and Risk of Parkinson's Disease. American Journal of Epidemiology, 2004, 160, 368-375.	1.6	60
285	Adjusted survival curves with inverse probability weights. Computer Methods and Programs in Biomedicine, 2004, 75, 45-49.	2.6	607
286	Recombinant hepatitis B vaccine and the risk of multiple sclerosis. Neurology, 2004, 63, 838-842.	1.5	267
287	A prospective study of alcoholism and the risk of Parkinson's disease. Journal of Neurology, 2004, 251, vii14-vii17.	1.8	41
288	Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Statistics in Medicine, 2004, 23, 749-767.	0.8	153

#	ARTICLE	IF	CITATIONS
289	A Structural Approach to Selection Bias. <i>Epidemiology</i> , 2004, 15, 615-625.	1.2	2,017
290	Weight loss in Parkinson's disease. <i>Annals of Neurology</i> , 2003, 53, 676-679.	2.8	242
291	Alcohol consumption and the incidence of Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, 170-175.	2.8	75
292	Infection with <i>Chlamydia pneumoniae</i> and Risk of Multiple Sclerosis. <i>Epidemiology</i> , 2003, 14, 141-147.	1.2	66
293	Dietary Intakes of Fat and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2003, 157, 1007-1014.	1.6	107
294	Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 1059.	4.9	545
295	Case-Crossover and Case-Time-Control Designs in Birth Defects Epidemiology. <i>American Journal of Epidemiology</i> , 2003, 158, 385-391.	1.6	57
296	Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models. <i>American Journal of Epidemiology</i> , 2003, 158, 687-694.	1.6	234
297	Title is missing!. <i>Epidemiology</i> , 2003, 14, 141-147.	1.2	50
298	Fallibility in estimating direct effects. <i>International Journal of Epidemiology</i> , 2002, 31, 163-165.	0.9	494
299	Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology. <i>American Journal of Epidemiology</i> , 2002, 155, 176-184.	1.6	1,107
300	Intake of Wine, Beer, and Spirits and the Risk of Clinical Common Cold. <i>American Journal of Epidemiology</i> , 2002, 155, 853-858.	1.6	45
301	Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. <i>Lancet</i> , The, 2002, 359, 1173-1177.	6.3	974
302	Methotrexate treatment and mortality in rheumatoid arthritis. <i>Lancet</i> , The, 2002, 360, 1097-1098.	6.3	5
303	Detection of Pulmonary Tuberculosis in Chiapas, Mexico. <i>Annals of Epidemiology</i> , 2002, 12, 166-172.	0.9	24
304	A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. <i>Annals of Neurology</i> , 2002, 52, 276-284.	2.8	656
305	Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. <i>Statistics in Medicine</i> , 2002, 21, 1689-1709.	0.8	257
306	Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments. <i>Journal of the American Statistical Association</i> , 2001, 96, 440-448.	1.8	373

#	ARTICLE	IF	CITATIONS
307	Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. <i>Annals of Neurology</i> , 2001, 50, 780-786.	2.8	154
308	Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. <i>Annals of Neurology</i> , 2001, 50, 56-63.	2.8	571
309	Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 3083.	3.8	468
310	Factors Associated With Noncompliance With Psychiatric Outpatient Visits. <i>Psychiatric Services</i> , 2001, 52, 378-380.	1.1	75
311	Hepatitis B Vaccination and the Risk of Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2001, 344, 327-332.	13.9	396
312	Food frequency consumption and lipoproteins serum levels in the population of an urban area, Brazil. <i>Revista De Saude Publica</i> , 2000, 34, 380-387.	0.7	37
313	Dietary Fat in Relation to Risk of Multiple Sclerosis among Two Large Cohorts of Women. <i>American Journal of Epidemiology</i> , 2000, 152, 1056-1064.	1.6	108
314	Childhood Malnutrition and Postwar Reconstruction in Rural El Salvador. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 184.	3.8	19
315	CT in the Evaluation of the Upper Airway in Healthy Subjects and in Patients With Obstructive Sleep Apnea Syndrome. <i>Chest</i> , 1998, 113, 111-116.	0.4	93
316	Efficacy of Antenatal Zidovudine in Reducing Perinatal Transmission of Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 1995, 172, 353-358.	1.9	89
317	Effectiveness of a second dose of an mRNA vaccine against SARS-CoV-2 Omicron infection in individuals previously infected by other variants. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	3